-
公开(公告)号:US20100210592A1
公开(公告)日:2010-08-19
申请号:US12703802
申请日:2010-02-11
IPC分类号: A61K31/44 , C07D211/70 , C07D401/04 , C07D211/22 , C07D239/26 , C07D413/04 , A61K31/444 , A61K31/445 , A61K31/505 , A61K31/5377 , A61P25/18 , A61P25/28 , A61K31/695
CPC分类号: A61K31/16 , C07C215/30 , C07C215/68 , C07C217/70 , C07C233/43 , C07C237/30 , C07C317/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D211/46 , C07D213/38 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/71 , C07D213/73 , C07D239/26 , C07D277/28 , C07D305/06 , C07D307/12 , C07D307/20 , C07D309/06 , C07D309/12 , C07D333/20 , C07D335/02 , C07D405/12
摘要: The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.
摘要翻译: 本发明涉及式I化合物的用途,其中取代基在描述和权利要求中描述用于治疗精神病,记忆障碍和学习功能障碍,精神分裂症,痴呆,注意力缺陷障碍或阿尔茨海默病。 本发明还涉及一些式I化合物和含有它们的药物组合物。
-
公开(公告)号:US20100048531A1
公开(公告)日:2010-02-25
申请号:US12541202
申请日:2009-08-14
IPC分类号: A61K31/397 , C07D405/04 , A61K31/4025 , A61K31/40 , C07D207/09 , C07D491/107
CPC分类号: C07D305/08 , C07D231/14 , C07D241/42 , C07D295/033 , C07D319/18 , C07D333/54 , C07D491/107 , C07D498/16
摘要: The present invention relates to a compound of formula I wherein R1, R2, X, Ar1 and Ar2 are as defined herein and to pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to their corresponding enantiomers and/or optical isomers thereof. Compounds of the invention are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.
摘要翻译: 本发明涉及式I化合物,其中R 1,R 2,X,Ar 1和Ar 2如本文所定义,和其药学上可接受的酸加成盐,涉及外消旋混合物或其相应的对映体和/或光学异构体。 本发明化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。
-
公开(公告)号:US08367838B2
公开(公告)日:2013-02-05
申请号:US13480520
申请日:2012-05-25
IPC分类号: C07D213/00 , C07D213/63 , C07D405/00 , A61K31/44
CPC分类号: A61K31/16 , C07C215/30 , C07C215/68 , C07C217/70 , C07C233/43 , C07C237/30 , C07C317/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D211/46 , C07D213/38 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/71 , C07D213/73 , C07D239/26 , C07D277/28 , C07D305/06 , C07D307/12 , C07D307/20 , C07D309/06 , C07D309/12 , C07D333/20 , C07D335/02 , C07D405/12
摘要: The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.
摘要翻译: 本发明涉及式I化合物的用途,其中取代基在描述和权利要求中描述用于治疗精神病,记忆障碍和学习功能障碍,精神分裂症,痴呆,注意力缺陷障碍或阿尔茨海默病。 本发明还涉及一些式I化合物和含有它们的药物组合物。
-
公开(公告)号:US08063098B2
公开(公告)日:2011-11-22
申请号:US12541202
申请日:2009-08-14
IPC分类号: A61K31/40 , C07D207/04
CPC分类号: C07D305/08 , C07D231/14 , C07D241/42 , C07D295/033 , C07D319/18 , C07D333/54 , C07D491/107 , C07D498/16
摘要: The present invention relates to a compound of formula I wherein R1, R2, X, Ar1 and Ar2 are as defined herein and to pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to their corresponding enantiomers and/or optical isomers thereof. Compounds of the invention are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.
摘要翻译: 本发明涉及式I化合物,其中R 1,R 2,X,Ar 1和Ar 2如本文所定义,和其药学上可接受的酸加成盐,涉及外消旋混合物或其相应的对映体和/或光学异构体。 本发明化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。
-
公开(公告)号:US20110313165A1
公开(公告)日:2011-12-22
申请号:US13161534
申请日:2011-06-16
申请人: Sabine Kolczewski , Emmanuel Pinard
发明人: Sabine Kolczewski , Emmanuel Pinard
IPC分类号: C07D471/04 , C07D455/00
CPC分类号: C07D455/02 , C07D471/04
摘要: The present invention relates to a compound of formula I-A or I-B wherein X, R1, R2 and R3 are defined herein; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. The compounds of formulas I-A and I-B are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors, suitable in the treatment of neurological and neuropsychiatric disorders.
摘要翻译: 本发明涉及式I-A或I-B化合物,其中X,R 1,R 2和R 3在本文中定义; 或其药学上可接受的酸加成盐,或其相应的对映异构体和/或其旋光异构体。 式I-A和I-B的化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,并且对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性,适用于治疗神经和神经精神障碍。
-
公开(公告)号:US08143273B2
公开(公告)日:2012-03-27
申请号:US13161534
申请日:2011-06-16
申请人: Sabine Kolczewski , Emmanuel Pinard
发明人: Sabine Kolczewski , Emmanuel Pinard
IPC分类号: A61K31/44 , C07D217/02
CPC分类号: C07D455/02 , C07D471/04
摘要: The present invention relates to a compound of formula I-A or I-B wherein X, R1, R2 and R3 are defined herein; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. The compounds of formulas I-A and I-B are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors, suitable in the treatment of neurological and neuropsychiatric disorders.
摘要翻译: 本发明涉及式I-A或I-B化合物,其中X,R 1,R 2和R 3在本文中定义; 或其药学上可接受的酸加成盐,或其相应的对映异构体和/或其旋光异构体。 式I-A和I-B的化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,并且对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性,适用于治疗神经和神经精神障碍。
-
公开(公告)号:US20110312993A1
公开(公告)日:2011-12-22
申请号:US13160559
申请日:2011-06-15
申请人: Sabine Kolczewski , Emmanuel Pinard
发明人: Sabine Kolczewski , Emmanuel Pinard
IPC分类号: A61K31/46 , A61P25/00 , A61P25/18 , C07D451/02 , A61P25/28
CPC分类号: C07D451/02 , A61K9/2018 , A61K9/2054 , A61K9/4858 , A61K9/4866
摘要: The present invention relates to a compound of formula I wherein R1, R2 and R3 are each independently hydrogen, lower alkyl, lower alkoxy, cycloalkyl, lower alkyl substituted by halogen or S-lower alkyl; or to a pharmaceutically acceptable acid addition salt, racemic mixture, or corresponding enantiomer and/or optical isomer thereof. The compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. The compounds can be used in the treatment of neurological and neuropsychiatric disorders.
摘要翻译: 本发明涉及式I化合物,其中R 1,R 2和R 3各自独立地为氢,低级烷基,低级烷氧基,环烷基,被卤素或S-低级烷基取代的低级烷基; 或其药学上可接受的酸加成盐,外消旋混合物或其相应的对映异构体和/或其光学异构体。 式I化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。 该化合物可用于治疗神经和神经精神障碍。
-
公开(公告)号:US20120022042A1
公开(公告)日:2012-01-26
申请号:US13249279
申请日:2011-09-30
申请人: Sabine Kolczewski , Emmanuel Pinard
发明人: Sabine Kolczewski , Emmanuel Pinard
IPC分类号: A61K31/40 , C07D295/155 , A61P25/28 , A61K31/397 , A61P25/18 , A61P25/00 , C07D207/09 , A61K31/5375
CPC分类号: A61K31/166 , A61K31/397 , A61K31/40 , A61K31/4453 , A61K31/495 , A61K31/5375 , C07C233/79 , C07C235/62 , C07C323/62 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/06 , C07D207/10 , C07D207/12 , C07D211/38 , C07D211/46 , C07D295/12 , C07D295/20 , C07D309/14 , C07D335/02 , C07D487/10
摘要: The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.
摘要翻译: 本发明涉及其中R 1,R 2,R 3,R 4,X和n如本文所定义或其药学上可接受的酸加成盐的式I化合物与外消旋混合物或其相应的对映体和/ 或用于治疗精神病,疼痛,记忆功能障碍和学习,注意力缺陷,精神分裂症,痴呆症或阿尔茨海默病的光学异构体。
-
公开(公告)号:US20100197715A1
公开(公告)日:2010-08-05
申请号:US12690128
申请日:2010-01-20
IPC分类号: A61K31/445 , A61K31/438 , A61K31/4545 , A61K31/4525 , A61K31/451 , C07D221/20 , C07D405/04 , C07D401/04 , C07D417/10 , C07D211/56 , A61P25/18 , A61P25/28 , A61P25/00
CPC分类号: C07D407/04 , A61K31/451 , C07D211/56 , C07D213/56 , C07D221/20 , C07D401/04 , C07D401/12 , C07D405/04 , C07D417/10
摘要: The present invention relates to a compound of formula I wherein R1, R2, and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. These compounds and their pharmaceutical compositions are useful in the treatment of neurological and neuropsychiatric disorders.
摘要翻译: 本发明涉及其中R 1,R 2和Ar如本文所定义或其药学上可接受的酸加成盐的式I化合物与外消旋混合物或其相应的对映异构体和/或其光学异构体。 这些化合物及其药物组合物可用于治疗神经和神经精神障碍。
-
公开(公告)号:US08524909B2
公开(公告)日:2013-09-03
申请号:US13010864
申请日:2011-01-21
申请人: Sabine Kolczewski , Emmanuel Pinard
发明人: Sabine Kolczewski , Emmanuel Pinard
IPC分类号: C07D401/04 , C07D209/52 , C07D405/04 , C07D309/14 , A61K31/4453 , A61K31/403 , A61K31/4025 , A61K31/351
CPC分类号: A61K31/351 , A61K9/2018 , A61K9/4858 , A61K31/4025 , A61K31/439 , A61K31/4412 , A61K31/4433 , C07D309/14 , C07D405/04
摘要: The present invention relates to a compound of formula I wherein R1/R2 are independently from each other hydrogen, (CR2)o-cycloalkyl, optionally substituted by lower alkyl or hydroxy, or are lower alkyl or heterocycloalkyl, and o is 0 or 1; and R may be the same or different and is hydrogen or lower alkyl; or R1 and R2 may form together with the N atom to which they are attached a heterocycloalkyl group, selected from the group consisting of pyrrolidinyl, piperidinyl, 3-aza-bicyclo[3.1.0]hex-3-yl or 2-aza-bicyclo[3.1.0]hex-2-yl, which are optionally substituted by hydroxy; R3 is S-lower alkyl, lower alkyl, lower alkoxy or cycloalkyl; R3′ is hydrogen, lower alkyl substituted by halogen, lower alkyl or lower alkoxy R4 is lower alkyl substituted by halogen, lower alkyl or lower alkoxy; X is —O— or —CH2—; X′ is —O— or —CH2—; with the proviso that one of X or X′ is always —O— and the other is —CH2—; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. It has been found that the compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1) and therefore they may be used for the treatment of schizophrenia.
摘要翻译: 本发明涉及式I化合物,其中R 1 / R 2彼此独立地为氢,(CR 2)o - 环烷基,任选被低级烷基或羟基取代,或为低级烷基或杂环烷基,o为0或1; 并且R可以相同或不同,为氢或低级烷基; 或者R 1和R 2可以与它们所连接的N原子一起形成杂环烷基,该杂环烷基选自吡咯烷基,哌啶基,3-氮杂 - 双环[3.1.0]己-3-基或2-氮杂 - 双环[3.1.0]己-2-基,其任选被羟基取代; R3是S-低级烷基,低级烷基,低级烷氧基或环烷基; R3'是氢,被卤素取代的低级烷基,低级烷基或低级烷氧基R4是被卤素,低级烷基或低级烷氧基取代的低级烷基; X是-O-或-CH 2 - ; X'是-O-或-CH 2 - ; 条件是X或X'中的一个总是-O-,另一个是-CH 2 - ; 或其药学上可接受的酸加成盐,或其相应的对映异构体和/或其旋光异构体。 已经发现,式I化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,因此它们可用于治疗精神分裂症。
-
-
-
-
-
-
-
-
-